Quadrivalent recombinant vaccin

Gardasil was approved by the FDA in 2006. It is a quadrivalent recombinant vaccine against the human papilloma vims (HPV), more specifically against types 6, 11, 16 and 18. It is able to reduce pre-cancerous cervical, vaginal and vulvar lesions, associated with HPV types 16 and 18, as well as condylomas associated with HPV types 6 and 11. With the approval of the first HPV vaccine, cervical cancer now has a primary prevention tool. 

Siddiqui MA, Perry CM (2006) Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Drugs 66 1263-1271... 

Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, Izurieta HS, Ball R, Miller N, Braun MM, Markowitz LE, Iskander J. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009 302 750-7. 

---